Bisaro Paul 4

What Happened
Paul Bisaro, a director of Myriad Genetics (NASDAQ: MYGN), purchased 7,500 shares in an open-market transaction on May 14, 2026 at $3.69 per share, for a total outlay of $27,638. The transaction is reported on a Form 4 with code P (purchase), indicating an acquisition rather than a sale.

Key Details

• Transaction date: 2026-05-14
• Transaction type/code: Open-market purchase (Form 4 code P)
• Shares bought: 7,500 at $3.69 per share — total $27,638
• Shares owned after transaction: Not specified in the provided filing
• Footnotes / trading plan: No 10b5-1 plan or other footnotes disclosed in the provided data
• Timeliness: Reported for the same date as the transaction; filing does not indicate lateness

Context
Insider purchases are often watched by retail investors as a potential positive signal, but this purchase is modest in dollar size relative to typical institutional trades. The filing is a straightforward buy; it does not include additional details (e.g., a trading plan) that would explain timing or intent.